Details of the Drug Reposition

General Information of This Drug (ID: DME47TX)

Drug Name
RG7112   DME47TX
Synonyms
RO5045337; QBGKPEROWUKSBK-QPPIDDCLSA-N; 939981-39-2; UNII-Q8MI0X869M; Q8MI0X869M; RO-5045337; CHEMBL2386346; Ro 5045337; GTPL9599; SCHEMBL12704861; DTXSID60240182; MolPort-044-560-282; EX-A1686; s7030; ZINC96270381; BDBM50434287; AKOS027282701; CS-0330; HY-10959; RG7112 (RO5045337); [(4s,5r)-2-(4-t-butyl-2-ethoxyphenyl)-4,5-bis(4-chlorophenyl)-4,5-dimethylimidazol-1-yl]-[4-(3-methylsulfonylpropyl)piperazin-1-yl]methanone; Methanone, [(4S,5R)-4,5-bis(4-chlorophenyl)-2-[4-(1,1-dimethylethyl)-2-ethoxyphenyl]
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Haematological malignancy DISCDP7W 2B33.Y Phase 1 [1]
------------------------------------------------------------------------------------
1 Discontinued in Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Discontinued in Phase 1 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT00559533) A Study of RO5045337 [RG7112] in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
2 Small molecules, big targets: drug discovery faces the protein-protein interaction challenge.Nat Rev Drug Discov. 2016 Aug;15(8):533-50.